{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:10:25Z","timestamp":1778652625236,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National High Level Hospital Clinical Research Fundin","award":["2022-GSP-GG-29"],"award-info":[{"award-number":["2022-GSP-GG-29"]}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2023-GSP-QN-14"],"award-info":[{"award-number":["2023-GSP-QN-14"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-1-001"],"award-info":[{"award-number":["2023-I2M-1-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08206-x","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:15:26Z","timestamp":1778516126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic profiling identifies molecular subtypes and unveils mechanistic insights into clinical features of hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"24","author":[{"given":"Xinli","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changpeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changrong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"6","key":"8206_CR1","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/CIRCGENETICS.115.001093","volume":"8","author":"J Ingles","year":"2015","unstructured":"Ingles J, et al. Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection. Circ Cardiovasc Genet. 2015;8(6):852\u20139.","journal-title":"Circ Cardiovasc Genet"},{"issue":"39","key":"8206_CR2","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733\u201379. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).","journal-title":"Eur Heart J"},{"issue":"14","key":"8206_CR3","doi-asserted-by":"publisher","first-page":"e34727","DOI":"10.1016\/j.heliyon.2024.e34727","volume":"10","author":"X Guo","year":"2024","unstructured":"Guo X, et al. MYH7 mutation is associated with mitral valve leaflet elongation in patients with obstructive hypertrophic cardiomyopathy. Heliyon. 2024;10(14):e34727.","journal-title":"Heliyon"},{"issue":"7 Pt 1","key":"8206_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jacep.2024.03.026","volume":"10","author":"IU Haq","year":"2024","unstructured":"Haq IU, et al. Atrial Fibrillation Substrate and Catheter Ablation Outcomes in MYBPC3- and MYH7-Mediated Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2024;10(7 Pt 1):1380\u201391.","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"8206_CR5","doi-asserted-by":"publisher","first-page":"e028293","DOI":"10.1161\/JAHA.122.028293","volume":"12","author":"M Huang","year":"2023","unstructured":"Huang M, et al. SARC Gene Mutation Is Associated With Myocardial Fibrosis Measured by Histopathology and Cardiac Magnetic Resonance in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2023;12(5):e028293.","journal-title":"J Am Heart Assoc"},{"issue":"50","key":"8206_CR6","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.3346\/jkms.2024.39.e313","volume":"39","author":"SY Gwak","year":"2024","unstructured":"Gwak SY, et al. Role of Genetic Testing in Diagnosis and Prognosis Prediction in Hypertrophic Cardiomyopathy in Korea. J Korean Med Sci. 2024;39(50):e313.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"8206_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cvr\/cvu127","volume":"103","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends ER, et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res. 2014;103(2):248\u201357.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"8206_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cge.13027","volume":"93","author":"M Sabater-Molina","year":"2018","unstructured":"Sabater-Molina M, et al. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet. 2018;93(1):3\u201314.","journal-title":"Clin Genet"},{"issue":"4","key":"8206_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ahj.2013.07.029","volume":"166","author":"JD Marsiglia","year":"2013","unstructured":"Marsiglia JD, et al. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy. Am Heart J. 2013;166(4):775\u201382.","journal-title":"Am Heart J"},{"key":"8206_CR10","doi-asserted-by":"crossref","unstructured":"Weissler-Snir A, et al. Lack of phenotypic differences by cardiovascular magnetic resonance imaging in MYH7 (\u03b2-myosin heavy chain)- versus MYBPC3 (myosin-binding protein C)-related hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(2).","DOI":"10.1161\/CIRCIMAGING.116.005311"},{"issue":"23","key":"8206_CR11","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.110.954446","volume":"122","author":"AP Landstrom","year":"2010","unstructured":"Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation. 2010;122(23):2441\u20139. discussion 2450.","journal-title":"Circulation"},{"issue":"7","key":"8206_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655\u201368.","journal-title":"N Engl J Med"},{"issue":"4","key":"8206_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11897-021-00523-0","volume":"18","author":"M Zampieri","year":"2021","unstructured":"Zampieri M, et al. Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Curr Heart Fail Rep. 2021;18(4):169\u201379.","journal-title":"Curr Heart Fail Rep"},{"issue":"14","key":"8206_CR14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387\u201398.","journal-title":"Circulation"},{"issue":"20","key":"8206_CR15","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jacc.2024.07.043","volume":"84","author":"HS Lumish","year":"2024","unstructured":"Lumish HS, et al. Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024;84(20):1999\u20132011.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"8206_CR16","doi-asserted-by":"publisher","first-page":"e009521","DOI":"10.1161\/CIRCHEARTFAILURE.121.009521","volume":"15","author":"MJ Previs","year":"2022","unstructured":"Previs MJ, et al. Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy. Circ Heart Fail. 2022;15(6):e009521.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"8206_CR17","doi-asserted-by":"publisher","first-page":"e003756","DOI":"10.1161\/CIRCGEN.122.003756","volume":"16","author":"R Garmany","year":"2023","unstructured":"Garmany R, et al. Multi-Omic Architecture of Obstructive Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2023;16(2):e003756.","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"8206_CR18","doi-asserted-by":"publisher","first-page":"e007022","DOI":"10.1161\/CIRCHEARTFAILURE.120.007022","volume":"14","author":"M Schuldt","year":"2021","unstructured":"Schuldt M, et al. Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy. Circ Heart Fail. 2021;14(1):e007022.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"8206_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1148\/radiol.10090526","volume":"258","author":"CJ Harrigan","year":"2011","unstructured":"Harrigan CJ, et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011;258(1):128\u201333.","journal-title":"Radiology"},{"issue":"3","key":"8206_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cardfail.2023.07.010","volume":"30","author":"C Lee","year":"2024","unstructured":"Lee C, et al. Signaling Pathways Associated With Prior Cardiovascular Events in Hypertrophic Cardiomyopathy. J Card Fail. 2024;30(3):462\u201372.","journal-title":"J Card Fail"},{"key":"8206_CR21","doi-asserted-by":"crossref","unstructured":"Lumish HS, et al. Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling. Europace. 2024;26(11).","DOI":"10.1093\/europace\/euae267"},{"issue":"24","key":"8206_CR22","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/heartjnl-2023-322644","volume":"109","author":"HS Lumish","year":"2023","unstructured":"Lumish HS, et al. Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics. Heart. 2023;109(24):1837\u201343.","journal-title":"Heart"},{"issue":"22","key":"8206_CR23","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1136\/heartjnl-2021-320729","volume":"108","author":"LW Liang","year":"2022","unstructured":"Liang LW, et al. Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart. 2022;108(22):1807\u201314.","journal-title":"Heart"},{"issue":"1","key":"8206_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","volume":"107","author":"F Sedaghat-Hamedani","year":"2018","unstructured":"Sedaghat-Hamedani F, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol. 2018;107(1):30\u201341.","journal-title":"Clin Res Cardiol"},{"key":"8206_CR25","doi-asserted-by":"crossref","unstructured":"Helms AS, et al. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy. JCI Insight. 2020;5(2).","DOI":"10.1172\/jci.insight.133782"},{"issue":"3","key":"8206_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/cvr\/cvt119","volume":"99","author":"ER Witjas-Paalberends","year":"2013","unstructured":"Witjas-Paalberends ER, et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res. 2013;99(3):432\u201341.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"8206_CR27","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1038\/s41598-023-40795-1","volume":"13","author":"R Garmany","year":"2023","unstructured":"Garmany R, et al. Proteomic and phosphoproteomic analyses of myectomy tissue reveals difference between sarcomeric and genotype-negative hypertrophic cardiomyopathy. Sci Rep. 2023;13(1):14341.","journal-title":"Sci Rep"},{"issue":"12","key":"8206_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrrheum.2012.184","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe B, D\u00f6rner T. Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. Nat Rev Rheumatol. 2012;8(12):738\u201346.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"8206_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.molimm.2014.06.036","volume":"61","author":"KT Lappeg\u00e5rd","year":"2014","unstructured":"Lappeg\u00e5rd KT, et al. A vital role for complement in heart disease. Mol Immunol. 2014;61(2):126\u201334.","journal-title":"Mol Immunol"},{"issue":"2","key":"8206_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/cvr\/cvr072","volume":"91","author":"ME Worou","year":"2011","unstructured":"Worou ME, et al. Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K\/Akt signalling. Cardiovasc Res. 2011;91(2):320\u20139.","journal-title":"Cardiovasc Res"},{"key":"8206_CR31","doi-asserted-by":"publisher","first-page":"111022","DOI":"10.1016\/j.biopha.2020.111022","volume":"133","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, et al. Qingda granule attenuates angiotensin II-induced cardiac hypertrophy and apoptosis and modulates the PI3K\/AKT pathway. Biomed Pharmacother. 2021;133:111022.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"8206_CR32","doi-asserted-by":"publisher","first-page":"230427","DOI":"10.1098\/rsob.230427","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, et al. MYH7 R453C induced cardiac remodelling via activating TGF-\u03b2\/Smad2\/3, ERK1\/2 and Nox4\/ROS\/NF-\u03baB signalling pathways. Open Biol. 2024;14(6):230427.","journal-title":"Open Biol"},{"issue":"10","key":"8206_CR33","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028","volume":"120","author":"P Teekakirikul","year":"2010","unstructured":"Teekakirikul P, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2. J Clin Invest. 2010;120(10):3520\u20139.","journal-title":"J Clin Invest"},{"key":"8206_CR34","doi-asserted-by":"crossref","unstructured":"Schlittler M, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: a perspective from fibroblasts. Int J Mol Sci. 2023;24(19).","DOI":"10.3390\/ijms241914845"},{"issue":"6","key":"8206_CR35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","volume":"1","author":"YJ Shimada","year":"2013","unstructured":"Shimada YJ, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480\u20137.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"8206_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/clc.22404","volume":"38","author":"B Ay\u00e7a","year":"2015","unstructured":"Ay\u00e7a B, et al. Increased Transforming Growth Factor-\u03b2 Levels Associated With Cardiac Adverse Events in Hypertrophic Cardiomyopathy. Clin Cardiol. 2015;38(6):371\u20137.","journal-title":"Clin Cardiol"},{"issue":"1","key":"8206_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.amjcard.2017.03.252","volume":"120","author":"Y Guo","year":"2017","unstructured":"Guo Y, et al. Usefulness of Preoperative Transforming Growth Factor-Beta to Predict New Onset Atrial Fibrillation After Surgical Ventricular Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(1):118\u201323.","journal-title":"Am J Cardiol"},{"issue":"13","key":"8206_CR38","doi-asserted-by":"publisher","first-page":"10860","DOI":"10.18632\/aging.205956","volume":"16","author":"H Dong","year":"2024","unstructured":"Dong H, et al. Identification of differentially expressed genes to predict the risk of heart failure in older patients with hypertrophic cardiomyopathy. Aging. 2024;16(13):10860\u20137.","journal-title":"Aging"},{"issue":"21","key":"8206_CR39","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1161\/CIRCULATIONAHA.121.053575","volume":"144","author":"S Ranjbarvaziri","year":"2021","unstructured":"Ranjbarvaziri S, et al. Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation. 2021;144(21):1714\u201331.","journal-title":"Circulation"},{"issue":"2","key":"8206_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1161\/CIRCRESAHA.119.315483","volume":"126","author":"J Ritterhoff","year":"2020","unstructured":"Ritterhoff J, et al. Metabolic Remodeling Promotes Cardiac Hypertrophy by Directing Glucose to Aspartate Biosynthesis. Circ Res. 2020;126(2):182\u201396.","journal-title":"Circ Res"},{"issue":"10","key":"8206_CR41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","volume":"141","author":"CN Toepfer","year":"2020","unstructured":"Toepfer CN, et al. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation. 2020;141(10):828\u201342.","journal-title":"Circulation"},{"key":"8206_CR42","doi-asserted-by":"crossref","unstructured":"Toepfer CN, et al. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci Transl Med. 2019;11(476).","DOI":"10.1126\/scitranslmed.aat1199"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08206-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:28:34Z","timestamp":1778650114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08206-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8206"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08206-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"672"}}